Scott R. Pancoast, CEO (and Company Founder and Board Member): Scott Pancoast was CEO and board member of Lpath [NASDAQ:LPTN] from 2005 through 2014 and was Chairman of the company from 1999 through 2010. He evolved this start-up from incubation at San Diego State University to eventual public-company status and raised about $150 million, with more than $50 million coming from non-dilutive government grants and from partnership proceeds. He forged worldwide partnerships with Merck-Serono and Pfizer and attracted equity investments from J&J and Biogen Idec. As EVP of Western States Investment Group from 1994 until 2004, he invested in and managed a portfolio of startups ranging from Endonetics (sold to Medtronic) to Mpex (sold to Axcan) to DermTech (currently in revenue ramp). He has served on over a dozen boards, including three public ones. Mr. Pancoast holds a BA in economics summa cum laude from the University of Virginia and an MBA with honors from Harvard Business School.
Thomas Murray, VP Business Development: Tom is an executive who has served in several leadership capacities over the years. Tom spent the early part of his career in a large corporation, primarily in sales, operations, and business development. Subsequently, he was one of three principals in a high-tech startup industry bringing a new device to market. In 2000, he landed at a nationwide sanitation services company and served as president of that organization for 13 years. Given that the average account size generated well over $1 million of annual revenues, Tom was the driving force of the business development and strategy functions. In 2013 he was instrumental in the sale of that organization to the largest competitor in that industry. He then served as an executive vice president for three years with that organization, overseeing a $210m operating unit, with about 4,000 employees covering the eastern third of the U.S. Over the last two years, Tom has consulted with two high-tech start-ups on business development and general strategic issues. Tom has a degree in political science from the University of Cincinnati.
John H. Lind, Ph.D., VP Operations and Planning: John served for the past 20 years in a variety of executive roles with Adhesives Research, Inc., a specialty developer and producer of coatings and adhesives for healthcare, electronics, and industrial applications. Eventually John assumed General Management responsibility for the company's wholly-owned pharmaceutical entity, ARx LLC, which developed and manufactured oral-mucosal delivery films and transdermal drug delivery systems. Improved operational execution and a refocused business yielded profitability in his first year, after years of losses, followed by a doubling of revenues in the subsequent two years. During his tenure, FDA facility/product audits yielded zero findings, and several new customer filings were granted regulatory approval. In 2015, he joined the ARx Board of Directors and assumed overall responsibility as President for the worldwide company. Prior to Adhesives Research, John worked for DuPont in R&D, marketing, sales, and planning leadership capacities. He has also served on a variety of Boards over the course of his career. John attended Duke University and was awarded a bachelor's degree in mechanical engineering as well as masters and doctoral degrees in materials science.
Joel M. Friedman, MD, PhD, Scientific Founder and Special Advisor—Basic Research: Joel Friedman, MD, PhD, is a Professor in the Department of Physiology and Biophysics and the Department of Medicine at the Albert Einstein College of Medicine. He also holds the Young Men’s Division Chair in Cardiovascular Physiology. He is a leading expert in the areas of molecular and protein biophysics, nitric oxide biochemistry, blood substitutes and nanotechnology. Dr. Friedman is the author of over 150 peer-reviewed scientific papers and is the co-inventor of the Nanopod™ delivery system. He has been the principle investigator on several NIH-funded program projects and R01’s. He is the head of the W.M. Keck-funded Biomolecular Laser Spectroscopy facility at the Albert Einstein College of Medicine and is on the selection committee for the Albany Prize. He is currently overseeing the further development and characterization of nanotechnology that is the foundation for new drug delivery and tissue imaging formulations.
Adam Friedman, MD, Scientific Founder and Special Advisor—Translational Research: Dr. Friedman is Associate Professor of Dermatology and serves as Residency Program Director, Director of Translational Research, and Director of the Supportive Oncodermatology Clinic in the Dept. of Dermatology at The George Washington University School of Medicine. Dr. Friedman is co-inventor of the Nanopod™ delivery system and is currently investigating novel treatments for infectious diseases, wound healing, and endothelial dysfunction. He holds multiple patents and has published over 160 papers/chapters and 2 textbooks. Dr. Friedman completed his undergraduate training at the Univ. of Pennsylvania and graduated with Distinction in Dermatologic Research at the Albert Einstein College of Medicine. During his residency at Einstein, he was appointed Chief Resident. He then joined the Einstein faculty, during which time he was the Director of Dermatologic Research, Director of the Translational Research Fellowship, and the Associate Program Director. Dr. Friedman lectures extensively in both national and international forums, and serves on a number of committees and advisory boards. He is a dermatology expert for healthguru.com, everydayhealth.com, and the Huffington Post, and hosts the online series titled “Ask an Expert” and the Journal of Drugs in Dermatology Podcast, “Ask an Investigator.”
Andrew Draganski, Ph.D., Head of Product Formulation: Andrew completed his Ph.D. in Food Science at Rutgers where he focused on studying molecular mobility in biological systems utilizing both intrinsic and GRAS-status optical probes. He then joined Joel Friedman's laboratory at Albert Einstein College of Medicine, where he worked on the advancement and further characterization of the lab's novel nanoparticle platform, and his efforts led to the current Nanopod(TM) platform that Zylö is now commercializing. He joined Zylö in early 2018 as Lead Scientist and shortly thereafter was promoted to his current position. He is especially interested in the effect of particle size, shape, charge distribution, surface functionalization, drug loading, and pore size on the subsequent interaction of nanoparticles, and related payloads, with cells and tissues.